Yale Cancer Center | Strategic Alliance Partners

Yale Cancer Center has appointed Ian E. Krop, MD, PhD, as Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs.

A Yale School of Medicine study showed sacituzumab govitecan could provide new options for treatment-resistant uterine cancer.

Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.

Experts highlight ctDNA-guided strategies, ADCs, and targeted therapies shaping CRC research in the first quarter of 2026.

Jan Philipp Bewersdorf, MD, FACP, detailed findings from a meta-analysis and considerations for the use of luspatercept for anemia in lower-risk MDS.

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.

David Rimm, MD, PhD, discusses ways that the use of ADCs in breast cancer might adapt to reflect emerging categories of detectable HER2 expression levels.

Researchers at Yale School of Medicine have identified biological markers for a rare, aggressive eye cancer that predicts secondary tumors in the liver.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

David Rimm, MD, PhD, discusses the strategic sequencing of ADCs in breast cancer, asserting that these agents should be classified as targeted therapies.

Drs Rotow and Woodard talk through recent updates to the perioperative non–small cell lung cancer treatment paradigm.

Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.

Yale Cancer Center researchers publish promising study of dual inhibition of PD1 and macrophage migration inhibitory factor.

Researchers developed a way to predict how lung cancer cells will respond to different therapies, allowing for more effective individualized treatment.

Drs Chiang and Liu discuss the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

Tracy Battaglia, MD, MPH, joined Yale Cancer Center’s Community Outreach and Engagement as associate director.

A Yale study published identified the mechanism underlying the relationship between the development of AMKL and a specific genetic alteration that occurs.

New tool by Yale researchers charts journey from pre-cancerous to advanced disease in animal models.

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

More than 2 dozen Yale experts are collaborating on a therapy for the most defended tumors.

A Yale study found that open-source AI tools outperformed traditional, visual methods for measuring the abundance of melanoma biomarkers.

A team of researchers at Yale developed and tested a new AI tool to help better characterize the diversity of individual tumor cells.

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

Yale School of Medicine announced the opening of the Yale Biomedical Imaging Institute, uniting imaging, clinical translation, and data science.

Juan Vasquez, MD, discusses how loss of NAPRT expression may serve as a biomarker for antitumor activity with NAMPT inhibition in rhabdomyosarcoma.

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.